Navigation Links
Cell Therapeutics, Inc. Announces Reverse Stock Split
Date:8/25/2008

Board of Directors approves 1-for-10 split ratio

SEATTLE, Aug. 25 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced that its Board of Directors has authorized a 1-for-10 reverse split of its common stock. The reverse split will become effective as of August 31, 2008.

At the Cell Therapeutics Special Meeting in Lieu of Annual Meeting of Shareholders held on June 19, 2008, shareholders approved a proposal to authorize the Board, in its discretion, to effect a reverse split of CTI's outstanding common stock without further action by shareholders.

The primary purpose of the reverse split is to increase the per-share trading price of CTI's stock in order to regain compliance with the NASDAQ Marketplace Rules for continued listing on the NASDAQ Global Market and to potentially appeal to a broader range of investors.

The reverse split will affect all outstanding shares of CTI's common stock as well as the number of shares of common stock underlying stock options and other exercisable or convertible instruments outstanding at the effective time of the reverse split but will not affect the number of authorized shares.

Upon the effectiveness of the reverse stock split, CTI shareholders will receive one new share of CTI common stock in exchange for every ten shares they hold. CTI's common stock will begin trading on a split-adjusted basis on the MTA in Milan on September 1, 2008 and will begin trading on a split-adjusted basis on the NASDAQ Global Market on September 2, 2008 under the temporary trading symbol "CTICD" in order to inform the investment community of the reverse stock split (MTA trading symbol shall not change). The trading symbol will revert to "CTIC" on September 30, 2008.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more t
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
2. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
3. Zenobia Therapeutics, Inc. Receives Michael J. Fox Foundation for Parkinsons Research Award for Work on PD-implicated Protein LRRK2
4. Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase $44.5 Million of Units Consisting of Senior Convertible Notes and Warrants
5. Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
6. Shareholders Approve All Matters Proposed by Cell Therapeutics, Inc. at Special Meeting in Lieu of Annual Meeting of Shareholders
7. Cell Therapeutics, Inc. Repays $11.0 million Balance of 2008 Convertible Debt
8. Cell Therapeutics, Inc. Special Meeting in Lieu of Annual Meeting of Shareholders Scheduled for Thursday, June 19, 2008
9. Cell Therapeutics, Inc. Announces Issuance of 2011 Convertible Senior Notes and Common Stock Warrants to a Single Institutional Investor
10. Anesiva and Transcription Factor Therapeutics, Inc. Announce Licensing Agreement for Development and Commercialization of NF-kappa B Clinical Program
11. Cell Therapeutics, Inc. (CTI) to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... SAN DIEGO and PRINCETON, N.J. ... Inc. (NASDAQ: OTCQB:AEMD), the pioneer in developing targeted therapeutic ... conditions, and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), ... the 2014 Exosomes & SingleCell Analysis Summit. ... of Exosome Sciences will give a presentation entitled: "Exosomes: ...
(Date:9/17/2014)... JH Technologies announces the grand ... JH Technologies, a leader in sales and support ... expanded partnership with Leica Microsystems into the Southern California ... solutions will be featured at the grand opening slated ... facility is located within the JH Technologies office’s at ...
(Date:9/17/2014)... -- Intarcia Therapeutics, Inc. today announced the ... the cost and predictability of non-adherence in type 2 ... of the European Association for the Study of Diabetes ... , Ph.D., of Analysis Group, Inc. presented data from ... studies to characterize the prevalence of non-adherence and serial ...
(Date:9/17/2014)... SOUTH SAN FRANCISCO, Calif. , Sept. 17, 2014 ... VCYT ), a molecular diagnostics company pioneering the field ... M. Hall to chief operating officer. Mr. ... to spearhead the company,s commercial entry into endocrinology. Since ... service operations, as well as managed care and billing ...
Breaking Biology Technology:Aethlon Medical and Exosome Sciences To Present at the Exosomes & SingleCell Analysis Summit 2Aethlon Medical and Exosome Sciences To Present at the Exosomes & SingleCell Analysis Summit 3JH Technologies displays newest microscope imaging technology at Southern California showroom grand opening 2JH Technologies displays newest microscope imaging technology at Southern California showroom grand opening 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 2Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 4Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 5Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 2Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 3Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 4
... uniform magnetic fields to drive iron-bearing nanoparticles to metal ... a drug payload that successfully prevents blockages in those ... better results at a lower dose than conventional non-magnetic ... the research is the latest in a series of ...
... ... creating an integration breakthrough with toxicology software and study-scaled capsule filling device. ... Greifensee, ... Data System (PDS) and METTLER TOLEDO (MT), global manufacturer of weighing technology, announce ...
... ... ... incredible chances to meet Taylor Swift . 100% of the proceeds will go towards the charity., ... 5/8 in Moline, IL 6/2 in Washington, D.C. This ...
Cached Biology Technology:Magnetic fields drive drug-loaded nanoparticles to reduce blood vessel blockages in an animal study 2Magnetic fields drive drug-loaded nanoparticles to reduce blood vessel blockages in an animal study 3Magnetic fields drive drug-loaded nanoparticles to reduce blood vessel blockages in an animal study 4Mettler Toledo and PDS Pathology Data Systems Integrate Powerful Solutions for Faster and More Accurate Preclinical Studies 2Mettler Toledo and PDS Pathology Data Systems Integrate Powerful Solutions for Faster and More Accurate Preclinical Studies 3Meet Taylor Swift! Concert Tickets with Meet and Greet Opportunities to Benefit City of Hope 2
(Date:9/17/2014)... great deal about complex social behavior by studying nonhuman ... teach too. , With their unusually large brains relative ... in a complex social environment---not merely in a large ... but in a dynamic setting of alliances and competitors. ... dolphins, whales, primates, and social carnivores, like hyenas and ...
(Date:9/16/2014)... Ohio (September 17, 2014)The North American Menopause Society ... the comprehensive care of midlife womenon everything from ... "The North American Menopause Society Recommendations for Clinical ... in the Society,s journal Menopause . This ... for the care of midlife women freely available ...
(Date:9/16/2014)... biology taught us that we inherit certain traits from ... could change how these genes play out by taking ... That,s exactly what a team of researchers at ... through their research of epigenetics research. , Epigenetics ... modifying DNA and histone proteins, which prevent permanent mutations ...
Breaking Biology News(10 mins):Being social: Learning from the behavior of birds 2Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 2Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 3
... impact on the diversity of beneficial microbial fungi known ... and maintenance of healthy ecosystems, according to new research ... Environmental Microbiology . The conclusions could have important implications ... tackle food security issues. The study was led ...
... FL. -- The first genetic study to compare nuclear ... manatees confirmed their designation as separate subspecies. Belize,s manatees, ... raising questions about their long-term genetic viability. The ... breeding population of Antillean manatees and is touted by ...
... University,s expanding research, education and entrepreneurial endeavors in ... of the Center for Photonics Innovation. The ... the center, which will combine university research and ... and engineering, and bioengineering. The center,s research ...
Cached Biology News:Farm management choice can benefit fungi key to healthy ecosystems 2Manatee subspecies genetically confirmed, but diversity challenge looms 2Manatee subspecies genetically confirmed, but diversity challenge looms 3Focus on photonics 2
... Jouan MSC series of Class II ... conditions and certification to the world's ... ensures that the cabinets cannot be ... Natural lighting, low noise and arm ...
...
... HM-4000 Multidizer is designed with a ... orbital, rotating - all in one unit. ... Two independently operating compartments allow for hybridization ... or motion , The upper chamber ...
... sleek design loaded with class-leading features, the 1400 Series ... work is safe and consistent every time you use ... 1400 Series reduces power consumption by as much as ... over the life of the cabinet. Multiply this ...
Biology Products: